Form 4: EXAGEN CEO Sells Shares for Tax Obligations

EXAGEN Inc. President and CEO John Aballi sold 31,787 shares of common stock at $11.8161 per share to cover tax withholding obligations from Restricted Stock Unit vesting.

Summary

• John Aballi, President and CEO, and a Director of EXAGEN Inc. (XGN), reported a transaction on October 16, 2025.
• The transaction involved the sale of 31,787 shares of EXAGEN Common Stock at a price of $11.8161 per share.
• The sale was explicitly stated as a 'sell to cover' transaction, mandated by the Issuer to satisfy tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).
• This was not a discretionary transaction by the Reporting Person.
• Following the reported transaction, John Aballi directly beneficially owns 714,427 shares of Common Stock.
• Additionally, 40,401 shares are indirectly beneficially owned by his spouse.

Sentiment

Score: 5

Explanation: The transaction is a mandatory 'sell to cover' for tax obligations related to RSU vesting, which is a routine and non-discretionary event. It does not reflect a change in management's outlook or the company's fundamentals, thus indicating a neutral sentiment.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ('RSUs').
• The sale is mandated by the Issuer's satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

Form 4 filings are standard disclosures for insiders (officers, directors, and 10% owners) reporting changes in their beneficial ownership of company securities. 'Sell to cover' transactions are common and routine events where insiders sell a portion of their vested equity awards to satisfy tax liabilities, rather than a discretionary sale indicating a change in sentiment about the company's prospects.

Stakeholder Impact

• Shareholders: The sale is a routine, non-discretionary event for tax purposes and is unlikely to have a significant impact on shareholder perception or the company's valuation.
• Employees: The RSU vesting and subsequent tax-related sale are part of standard executive compensation practices.

Key Dates

Recommendation

The filing reports a mandatory 'sell to cover' transaction by the CEO to satisfy tax obligations related to RSU vesting. This is a routine event and does not reflect a discretionary sale or a change in the company's fundamentals, thus it does not warrant a change in investment recommendation. Investors should continue to evaluate EXAGEN based on its operational performance and strategic outlook.

Keywords

EXAGEN, XGN, John Aballi, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding